Fiche publication
Date publication
janvier 2026
Journal
Chemical communications (Cambridge, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel
,
Dr FROCHOT Céline
,
Pr NOEL Georges
,
Dr BURCKEL Hélène
,
Dr DAOUK Joël
,
Dr CZUBA Elodie
Tous les auteurs :
Sarr S, Godard J, Valzer E, Czuba E, Acherar S, Barberi-Heyob M, Blanchard-Desce M, Boleslawski E, Brégier F, Bulin AL, Burckel H, Daouk J, da Silva A, Daniel J, Delhem N, Dewalle AS, Frochot C, Gasser G, Heitz V, Jonckheere N, Lemercier G, Mordon S, Noël G, Novell A, Ravanat JL, Roth G, Sol V
Lien Pubmed
Résumé
Photodynamic therapy (PDT) is a clinically-approved medical modality to treat different types of localised conditions such as cancer, infections or skin conditions. Pancreatic cancer (PC) is a deadly cancer displaying a dramatic overall prognosis that has barely improved in decades as the majority of PC patients are diagnosed at a locally advanced or metastatic stage and cannot benefit of surgical resection which is the only curative treatment, the overall 5-year survival rate remains extremely low. Thus, finding new therapies for non-metastatic PC to improve local control as a bridge to surgical resection and improve survival outcomes remains a huge challenge. In this context, PDT could be an interesting option. This review will focus on the use of PDT with targeted photosensitisers or nanoparticles to treat PC in recent studies (2020-2025) from to experiments and clinical applications.
Référence
Chem Commun (Camb). 2026 01 22;:
